한글목차

장기 이식용 면역억제제 시장 규모는 최근 꾸준히 성장하고 있습니다. 2025년 54억 7,000만 달러에서 2026년에는 56억 8,000만 달러에 이르고, CAGR 3.9%의 성장이 전망되고 있습니다. 지난 수년간의 성장세는 장기이식 수술 건수 증가, 칼시뉴린 억제제 치료의 발전, 말기 장기부전 환자 증가, 이식 후 생존율 향상, 이식센터 확대 등이 주요 요인으로 꼽힙니다.

장기 이식용 면역억제제 시장 규모는 향후 몇 년간 꾸준한 성장이 전망됩니다. 2030년에는 68억 5,000만 달러에 이르고, CAGR은 4.8%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 정밀 면역 억제 프로토콜의 보급, 생물학적 제제 기반 치료법의 채택 증가, 신흥 시장에서의 헬스케어 지출 증가, 온라인 약국 유통 확대, 저독성 면역억제제 혁신 등이 있습니다. 예측 기간의 주요 동향으로는 표적 지향적 면역억제요법으로의 전환, 병용요법 선호도 증가, 제네릭 의약품 및 바이오시밀러 면역억제제의 성장, 장기 이식편 생존율에 대한 관심 증가, 병원 중심의 이식 치료 모델 확대 등을 꼽을 수 있습니다.

장기 이식에 대한 수요 증가는 장기이식용 면역억제제 시장의 성장을 견인할 것으로 예측됩니다. 장기이식은 손상되거나 질병에 걸린 장기를 기증자로부터 기증받은 건강한 장기로 대체하는 수술입니다. 장기부전 환자의 장기 기능을 회복시켜 생명을 살리는 치료법입니다. 면역억제제는 이식된 장기를 면역체계가 거부반응을 일으키는 것을 방지함으로써 장기이식에서 매우 중요한 역할을 합니다. 이 거부반응이 발생하면 이식 실패로 이어질 수 있습니다. 따라서 이러한 약물의 가용성과 효능은 이식 수술의 성공에 필수적인 요소입니다. 예를 들어, 미국에 본사를 둔 민관 협력 조직인 장기 조달 이식 네트워크(OPTN)에 따르면, 2023년 약 16,335명의 개인이 사망 후 1개 이상의 장기를 기증했습니다. 이는 사망 기증자 수가 처음으로 15,000명을 넘어선 것으로, 2022년 대비 9.6% 증가한 수치입니다. 이에 따라 장기 이식에 대한 수요가 증가하면서 장기이식용 면역억제제 시장의 성장을 가속하고 있습니다.

제품 혁신은 장기이식용 면역억제제 시장의 주요 트렌드입니다. 이 시장에서 활동하는 주요 기업들은 시장에서의 입지를 유지하기 위해 병용요법 등 혁신적인 치료법 개발에 주력하고 있습니다. 두 가지 이상의 면역억제제를 병용하는 병용요법은 면역억제 효과를 높이면서 부작용의 위험을 최소화할 수 있어 주목받고 있습니다. 예를 들어, 2024년 3월, 미국에 본사를 둔 제약 및 생명공학 기업 존슨앤드존슨은 미국 식품의약국(FDA)으로부터 'OPSYNVI'의 승인을 받았습니다. OPSYNVI는 폐동맥성 고혈압(PAH)의 장기 치료를 목적으로 하는 포스포디에스터라아제5 억제제(PDE5 억제제)인 타다라필과 엔도세린 수용체 길항제인 마스티텐탄을 병용하는 단일제 병용요법입니다. 이 약은 치료 경험이 없거나 현재 엔도세린 수용체 길항제(ERA), 포스포디에스터라아제5 억제제(PDE5 억제제) 또는 둘 다 복용 중인 환자를 대상으로 합니다. 이미 마티텐탄 10mg과 타다라필 40mg을 따로 복용하고 있는 환자에게도 OPSYNVI 처방이 가능합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Organ transplant immunosuppressant drugs are medicines used to weaken the immune system of transplant recipients in order to prevent the body from rejecting a transplanted organ.

The major classes of organ transplant immunosuppressant drugs include calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Calcineurin is an enzyme that plays a critical role in activating T cells, which are immune cells capable of attacking transplanted organs. Calcineurin inhibitors are a class of immunosuppressant medications used to reduce the risk of organ rejection in transplant patients. These drugs are used in heart, kidney, liver, lung, pancreas, and other organ transplants and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have introduced cost pressures in the organ transplant immunosuppressant drugs market by increasing prices of imported active pharmaceutical ingredients, biologics, and specialized manufacturing inputs, impacting drug affordability and hospital procurement budgets. The effect is more pronounced across biologic-based therapies, calcineurin inhibitors, and mTOR inhibitors, with Asia-Pacific and Latin America most affected due to reliance on imported APIs and finished formulations. However, tariffs have also encouraged regional manufacturing, increased generic drug production, and strengthened local supply chains, creating long-term opportunities for cost optimization and domestic pharmaceutical growth.

The organ transplant immunosuppressant drugs market research report is one of a series of new reports from The Business Research Company that provides organ transplant immunosuppressant drugs market statistics, including organ transplant immunosuppressant drugs industry global market size, regional shares, competitors with a organ transplant immunosuppressant drugs market share, detailed organ transplant immunosuppressant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the organ transplant immunosuppressant drugs industry. This organ transplant immunosuppressant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The organ transplant immunosuppressant drugs market size has grown steadily in recent years. It will grow from $5.47 billion in 2025 to $5.68 billion in 2026 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to increase in organ transplant procedures, advancement in calcineurin inhibitor therapies, rising prevalence of end-stage organ failure, improved post-transplant survival rates, expansion of transplant centers.

The organ transplant immunosuppressant drugs market size is expected to see steady growth in the next few years. It will grow to $6.85 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to growth in precision immunosuppression protocols, increasing adoption of biologic-based therapies, rising healthcare expenditure in emerging markets, expansion of online pharmacy distribution, innovation in low-toxicity immunosuppressant drugs. Major trends in the forecast period include shift toward targeted immunosuppressive therapies, rising preference for combination drug regimens, growth of generic and biosimilar immunosuppressants, increasing focus on long-term graft survival, expansion of hospital-centric transplant care models.

The growing demand for organ transplantation is expected to drive the growth of the organ transplant immunosuppressant drugs market. Organ transplantation is a surgical procedure in which a damaged or diseased organ is replaced with a healthy organ obtained from a donor. It is a life-saving intervention that restores organ function in patients with organ failure. Immunosuppressant drugs play a critical role in organ transplantation by preventing the immune system from rejecting the transplanted organ, which could otherwise lead to transplant failure. The availability and effectiveness of these drugs are therefore essential to the success of transplant procedures. For instance, in 2023, according to the Organ Procurement and Transplantation Network (OPTN), a US-based public-private partnership organization, approximately 16,335 individuals donated one or more organs after death. This marked the first time the number of deceased donors exceeded 15,000, representing a 9.6% increase compared to 2022. As a result, the increasing demand for organ transplantation is fueling the growth of the organ transplant immunosuppressant drugs market.

Product innovation is a key trend in the organ transplant immunosuppressant drugs market. Major companies operating in this market are focusing on developing innovative treatment approaches, such as combination therapies, to maintain their market presence. Combination therapy, which involves the use of two or more immunosuppressant drugs, is gaining traction as it can enhance immunosuppressive effectiveness while minimizing the risk of adverse side effects. For example, in March 2024, Johnson & Johnson, a US-based pharmaceutical and biotechnology company, received approval from the U.S. Food and Drug Administration for OPSYNVI. OPSYNVI is a single-tablet combination therapy containing tadalafil, a phosphodiesterase-5 inhibitor, and macitentan, an endothelin receptor antagonist, for the long-term treatment of pulmonary arterial hypertension (PAH). It is indicated for patients who are treatment-naive or those currently receiving an ERA, a PDE5 inhibitor, or both. Patients who are already taking stable doses of macitentan 10 mg and tadalafil 40 mg as separate tablets may also be prescribed OPSYNVI.

In July 2024, Biogen Inc., a US-based biotechnology company focused on therapies for neurological and immune-mediated diseases, acquired Human Immunology Biosciences (HI-Bio) for an undisclosed amount. Through this acquisition, Biogen aims to enhance its immunology portfolio by incorporating late-stage plasma cell-targeting therapies, thereby expanding its footprint in immune-mediated and transplant-related disease markets. Human Immunology Biosciences is a US-based biotechnology company specializing in targeted therapies for severe immune-mediated conditions, including antibody-mediated transplant rejection.

Major companies operating in the organ transplant immunosuppressant drugs market are Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, Pfizer Inc., Sanofi S.A., Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited

North America was the largest region in the organ transplant immunosuppressant drugs market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the organ transplant immunosuppressant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The organ transplant immunosuppressant drugs market consists of sales of drugs such as asteroid-sparing immunosuppressants, prednisone, antineoplastics, monoclonal antibody drugs, and immunosuppressive agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Organ Transplant Immunosuppressant Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses organ transplant immunosuppressant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for organ transplant immunosuppressant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The organ transplant immunosuppressant drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Calcineurin Inhibitors; Antiproliferative Agents; mTOR Inhibitor; Steroids; Other Drug Classes
• 2) By Transplant Type: Heart; Kidney; Liver; Lung; Pancreas; Other Transplant Types
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Calcineurin Inhibitors: Cyclosporine; Tacrolimus
• 2) By Antiproliferative Agents: Azathioprine; Mycophenolate Mofetil; Mycophenolic Acid
• 3) By MTOR Inhibitor: Sirolimus; Everolimus
• 4) By Steroids: Prednisone; Methylprednisolone
• 5) By Other Drug Classes: Costimulation Blockers; Sodium Channel Blockers; Antibody-Based Therapies
• Companies Mentioned: Astellas Pharma Inc.; F. Hoffmann-La Roche AG; Novartis AG; Accord Healthcare Limited; Pfizer Inc.; Sanofi S.A.; Neovii Pharmaceuticals AG; Zydus Lifesciences Limited; Dr. Reddy's Laboratories Ltd.; Lupin Limited; Mylan N.V.; Strides Pharma Global Pte Ltd.; Bristol-Myers Squibb Company; Veloxis Pharmaceuticals A/S; Viatris Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.; Wockhardt Ltd; Glenmark Pharmaceuticals Ltd.; Biocon Ltd.; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; Cipla Ltd.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Intas Pharmaceuticals Limited; Alkem Laboratories Limited; Torrent Pharmaceuticals Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Organ Transplant Immunosuppressant Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Organ Transplant Immunosuppressant Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Organ Transplant Immunosuppressant Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Organ Transplant Immunosuppressant Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Shift Toward Targeted Immunosuppressive Therapies
  • 4.2.2 Rising Preference For Combination Drug Regimens
  • 4.2.3 Growth Of Generic And Biosimilar Immunosuppressants
  • 4.2.4 Increasing Focus On Long-Term Graft Survival
  • 4.2.5 Expansion Of Hospital-Centric Transplant Care Models

5. Organ Transplant Immunosuppressant Drugs Market Analysis Of End Use Industries

• 5.1 Transplant Hospitals
• 5.2 Specialty Transplant Centers
• 5.3 Organ Transplant Clinics
• 5.4 Academic Medical Institutes
• 5.5 Ambulatory Surgical Centers

6. Organ Transplant Immunosuppressant Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Organ Transplant Immunosuppressant Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Organ Transplant Immunosuppressant Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Organ Transplant Immunosuppressant Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Organ Transplant Immunosuppressant Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Organ Transplant Immunosuppressant Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Organ Transplant Immunosuppressant Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Organ Transplant Immunosuppressant Drugs Market Segmentation

• 9.1. Global Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Other Drug Classes
• 9.2. Global Organ Transplant Immunosuppressant Drugs Market, Segmentation By Transplant Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Heart, Kidney, Liver, Lung, Pancreas, Other Transplant Types
• 9.3. Global Organ Transplant Immunosuppressant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.4. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cyclosporine, Tacrolimus
• 9.5. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Antiproliferative Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Azathioprine, Mycophenolate Mofetil, Mycophenolic Acid
• 9.6. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of mTOR Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sirolimus, Everolimus
• 9.7. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prednisone, Methylprednisolone
• 9.8. Global Organ Transplant Immunosuppressant Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Costimulation Blockers, Sodium Channel Blockers, Antibody-Based Therapies

10. Organ Transplant Immunosuppressant Drugs Market Regional And Country Analysis

• 10.1. Global Organ Transplant Immunosuppressant Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Organ Transplant Immunosuppressant Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market

• 11.1. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Organ Transplant Immunosuppressant Drugs Market

• 12.1. China Organ Transplant Immunosuppressant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Organ Transplant Immunosuppressant Drugs Market

• 13.1. India Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Organ Transplant Immunosuppressant Drugs Market

• 14.1. Japan Organ Transplant Immunosuppressant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Organ Transplant Immunosuppressant Drugs Market

• 15.1. Australia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Organ Transplant Immunosuppressant Drugs Market

• 16.1. Indonesia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Organ Transplant Immunosuppressant Drugs Market

• 17.1. South Korea Organ Transplant Immunosuppressant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Organ Transplant Immunosuppressant Drugs Market

• 18.1. Taiwan Organ Transplant Immunosuppressant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Organ Transplant Immunosuppressant Drugs Market

• 19.1. South East Asia Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Organ Transplant Immunosuppressant Drugs Market

• 20.1. Western Europe Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Organ Transplant Immunosuppressant Drugs Market

• 21.1. UK Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Organ Transplant Immunosuppressant Drugs Market

• 22.1. Germany Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Organ Transplant Immunosuppressant Drugs Market

• 23.1. France Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Organ Transplant Immunosuppressant Drugs Market

• 24.1. Italy Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Organ Transplant Immunosuppressant Drugs Market

• 25.1. Spain Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Organ Transplant Immunosuppressant Drugs Market

• 26.1. Eastern Europe Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Organ Transplant Immunosuppressant Drugs Market

• 27.1. Russia Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Organ Transplant Immunosuppressant Drugs Market

• 28.1. North America Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Organ Transplant Immunosuppressant Drugs Market

• 29.1. USA Organ Transplant Immunosuppressant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Organ Transplant Immunosuppressant Drugs Market

• 30.1. Canada Organ Transplant Immunosuppressant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Organ Transplant Immunosuppressant Drugs Market

• 31.1. South America Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Organ Transplant Immunosuppressant Drugs Market

• 32.1. Brazil Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Organ Transplant Immunosuppressant Drugs Market

• 33.1. Middle East Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Organ Transplant Immunosuppressant Drugs Market

• 34.1. Africa Organ Transplant Immunosuppressant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Organ Transplant Immunosuppressant Drugs Market, Segmentation By Drug Class, Segmentation By Transplant Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Organ Transplant Immunosuppressant Drugs Market Regulatory and Investment Landscape

36. Organ Transplant Immunosuppressant Drugs Market Competitive Landscape And Company Profiles

• 36.1. Organ Transplant Immunosuppressant Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Organ Transplant Immunosuppressant Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Organ Transplant Immunosuppressant Drugs Market Company Profiles
  • 36.3.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Accord Healthcare Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Organ Transplant Immunosuppressant Drugs Market Other Major And Innovative Companies

• Sanofi S.A., Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd.

38. Global Organ Transplant Immunosuppressant Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Organ Transplant Immunosuppressant Drugs Market

40. Organ Transplant Immunosuppressant Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Organ Transplant Immunosuppressant Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Organ Transplant Immunosuppressant Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Organ Transplant Immunosuppressant Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer